Test Predicts Response to Key Migraine Therapy With 86% Accuracy

Facebook Researchers from Harvard Medical School found non-ictal cephalic allodynia, established by a quick, inexpensive and noninvasive proprietary test, is an 86% accurate pretreatment predictor of anti-calcitonin gene–related peptide (CGRP) therapy response. To read the rest of the article head over to PainMedicineNews.com More to explorer